The Identification of certain chemical disruptors of the estrogen receptor α: Structural and docking analyses

  • Noora alyasari PhD. Candidate
Keywords: Breast cancer, estrogen receptor antagonists, milbemycin_A3_5-oxime.


Due to the active role of estrogen receptor α (ERα) in certain breast cancer, finding possible ERα antagonists is important for lowering the growth rate of ERα-motivated breast cancer cells. Here, the current work was conducted to computationally find ERα inhibitors based on the use of certain docking methods. The three-dimensional (3D)-ERα structure was freely docked with the 3D structure of certain ligands, including milbemycin_A3_5-oxime (MA), Baloxavir marboxil (BM), tadalafil (TF), sesamol (SM), raspberry ketone (RK), guaiacol (GuC), proanthocyanidins (PAC), epicatechin (EC), and catechin (CC). The results of the protein-ligand based binding affinity values (kcal/mol) revealed the following; MA= -9.7, TF= -8.5, BM= -8.2, PAC= -8.1, CC= -7.5, EC= -7.2, RK= -6.1, SM= -5.7, and GuC= -4.8. According to the above-mentioned data, milbemycin_A3_5-oxime, tadalafil, Baloxavir marboxil, and proanthocyanidins show the highest binding affinity, which can further be studied in vitro and in vivo for their proposed activity. In addition, catechin, epicatechin, raspberry ketone, sesamol, and guaiacol can also further be investigated for their anti-ERα activity, in which some structural modification to the ligand molecules can be performed to increase their binding action, if they show low ERα-based blocking via in vitro and in vivo research.


Download data is not yet available.


1. Jia M, Dahlman-Wright K, Gustafsson J-Å. Estrogen receptor alpha and beta in health and disease. Best Pract Res Clin Endocrinol Metab. 2015;29(4):557–568. DOI: 10.1016/j.beem.2015.04.008
2. Sellami A, Montes M, Lagarde N. Predicting Potential Endocrine Disrupting Chemicals Binding to Estrogen Receptor α (ERα) Using a Pipeline Combining Structure-Based and Ligand-Based in Silico Methods. Int J Mol Sci. 2021;22(6):2846. DOI: 10.3390/ijms22062846

3. Farzaneh S, Zarghi A. Estrogen receptor ligands: a review (2013–2015). Sci Pharm. 2016;84(3):409–427. DOI: 10.3390/scipharm84030409

4. Schug TT, Johnson AF, Birnbaum LS, Colborn T, Guillette Jr LJ, Crews DP, et al. Minireview: endocrine disruptors: past lessons and future directions. Mol Endocrinol. 2016;30(8):833–847. DOI: 10.1210/me.2016-1096

5. Fillol C, Oleko A, Saoudi A, Zeghnoun A, Balicco A, Gane J, et al. Exposure of the French population to bisphenols, phthalates, parabens, glycol ethers, brominated flame retardants, and perfluorinated compounds in 2014–2016: Results from the Esteban study. Environ Int. 2021; 147:106340.
DOI: 10.1016/j.envint.2020.106340
6. Audouze K, Sarigiannis D, Alonso-Magdalena P, Brochot C, Casas M, Vrijheid M, et al. Integrative strategy of testing systems for identification of endocrine disruptors inducing metabolic disorders—An introduction to the oberon project. Int J Mol Sci. 2020;21(8):2988. DOI: 10.3390/ijms21082988

7. Muñoz-Muñoz L, Shoen C, Sweet G, Vitoria A, Bull TJ, Cynamon M, et al. Repurposing avermectins and milbemycins against mycobacteroides abscessus and other nontuberculous mycobacteria. Antibiotics. 2021;10(4):381. DOI: 10.3390/antibiotics10040381

8. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787. DOI: 10.1016/j.antiviral.2020.104787

9. Długońska H. The Nobel Prize 2015 in physiology or medicine for highly effective antiparasitic drugs. Ann Parasitol. 2015;61(4):299–301. DOI: 10.17420/ap6104.23

10. Ōmura S, Crump A. Ivermectin: panacea for resource-poor communities? Trends Parasitol. 2014;30(9):445–55. DOI: 10.1016/

11. Li X-Q, Yue C-W, Xu W-H, Lü Y-H, Huang Y-J, Tian P, et al. A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549/DDP cells. Biomed Pharmacother. 2020; 128:110322.
DOI: 10.1016/j.biopha.2020.110322

12. Aversa A, Fittipaldi S, Bimonte VM, Wannenes F, Papa V, Francomano D, et al. Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model. J Endocrinol Invest. 2016;39(2):199–205. DOI: 10.1007/s40618-015-0344-1

13. Antinozzi C, Greco EA, Sgrò P, Dimauro I, Aversa A, Di Luigi L. Effects of Tadalafil on skeletal muscle tissue: Exploring interactions and novel mechanisms of action. Minerva Endocrinol. 2022;3698. DOI: 10.23736/S2724-6507.21.03698-8

14. Aversa A, Fittipaldi S, Francomano D, Bimonte VM, Greco EA, Crescioli C, et al. Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization. Endocrine. 2017;56(3):639–648.
DOI: 10.1007/s12020-016-1208-y

15.Aversa A, Caprio M, Antelmi A, Armani A, Brama M, Greco EA, et al. Exposure to phosphodiesterase type 5 inhibitors stimulates aromatase expression in human adipocytes in vitro. J Sex Med. 2011;8(3):696–704. DOI: 10.1111/j.1743-6109.2010.02152.x

16.Greco EA, Pili M, Bruzziches R, Corona G, Spera G, Aversa A. Testosterone: Estradiol ratio changes associated with long‐term tadalafil administration: A pilot study. J Sex Med. 2006;3(4):716–22. DOI: 10.1111/j.1743-6109.2006.00264.x

17.Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2007;19(2):200–7. DOI: 10.1038/sj.ijir.3901513

18.Maneschi E, Cellai I, Aversa A, Mello T, Filippi S, Comeglio P, et al. Tadalafil reduces visceral adipose tissue accumulation by promoting preadipocytes differentiation towards a metabolically healthy phenotype: studies in rabbits. Mol Cell Endocrinol. 2016; 424:50–70. DOI: 10.1016/j.mce.2016.01.015

19.Dufrasne F. Baloxavir marboxil: An original new drug against influenza. Pharmaceuticals. 2021;15(1):28. DOI: 10.3390/ph15010028

20.Losada-Echeberría M, Herranz-López M, Micol V, Barrajón-Catalán E. Polyphenols as promising drugs against main breast cancer signatures. Antioxidants. 2017;6(4):88. DOI: 10.3390/antiox6040088
How to Cite
alyasari, N. (2023). The Identification of certain chemical disruptors of the estrogen receptor α: Structural and docking analyses. Al-Qadisiyah Journal of Pure Science, 27(1), 45-62.